ID   Hs 700T
AC   CVCL_0858
SY   HS-700-T; Hs-700-T; Hs-700T; HS-700T; HS 700T; HS700T; Hs700T; 700T
DR   CLO; CLO_0004061
DR   ATCC; HTB-147
DR   BioSample; SAMN03472721
DR   cancercelllines; CVCL_0858
DR   Cosmic; 730528
DR   Cosmic; 947402
DR   Cosmic; 922262
DR   Cosmic; 1218872
DR   Cosmic; 1299300
DR   Cosmic; 1366276
DR   Cosmic; 2434106
DR   GEO; GSM621856
DR   GEO; GSM784697
DR   IARC_TP53; 314
DR   IZSLER; BS TCL 229
DR   PRIDE; PXD003198
DR   Progenetix; CVCL_0858
DR   Wikidata; Q54895906
RX   PubMed=176412;
RX   PubMed=283258;
RX   PubMed=761205;
RX   PubMed=1630814;
RX   PubMed=6500159;
RX   PubMed=7961102;
RX   PubMed=15126341;
RX   PubMed=15688027;
RX   PubMed=25167228;
RX   PubMed=27259358;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 4-5 days (PubMed=176412).
CC   Karyotypic information: Most chromosome counts are in the hypertetraploid range. A substantial (30%) population of hyperdiploid to hypotriploid cells is present (ATCC=HTB-147).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg249Met (c.746G>T); ClinVar=VCV000376653; Zygosity=Unspecified (PubMed=1630814; PubMed=7961102).
CC   Omics: Array-based CGH.
CC   Omics: Deep proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Miscellaneous: The mucin producing, primary tumor was thought to have originated from the intestines or pancreas (ATCC=HTB-147).
CC   Derived from site: Metastatic; Pelvis; UBERON=UBERON_0002355.
ST   Source(s): ATCC=HTB-147; IZSLER=BS TCL 229
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 8
ST   D16S539: 10,13
ST   D18S51: 13,18
ST   D19S433: 14
ST   D21S11: 28,31
ST   D2S1338: 17,24,25
ST   D3S1358: 18
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   D8S1179: 11,12,13
ST   FGA: 20,21,22
ST   Penta D: 9,13
ST   Penta E: 11
ST   TH01: 9.3
ST   TPOX: 8,12
ST   vWA: 18,19
DI   NCIt; C3262; Neoplasm
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0857 ! Hs 700.Sk
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 26
//
RX   PubMed=176412; DOI=10.1093/jnci/56.4.843;
RA   Owens R.B., Smith H.S., Nelson-Rees W.A., Springer E.L.;
RT   "Epithelial cell cultures from normal and cancerous human tissues.";
RL   J. Natl. Cancer Inst. 56:843-849(1976).
//
RX   PubMed=283258; DOI=10.1093/jnci/62.2.225;
RA   Smith H.S.;
RT   "In vitro properties of epithelial cell lines established from human
RT   carcinomas and nonmalignant tissue.";
RL   J. Natl. Cancer Inst. 62:225-230(1979).
//
RX   PubMed=761205;
RA   Smith H.S., Springer E.L., Hackett A.J.;
RT   "Nuclear ultrastructure of epithelial cell lines derived from human
RT   carcinomas and nonmalignant tissues.";
RL   Cancer Res. 39:332-344(1979).
//
RX   PubMed=1630814;
RA   Ruggeri B.A., Zhang S.-Y., Caamano J., DiRado M., Flynn S.D.,
RA   Klein-Szanto A.J.P.;
RT   "Human pancreatic carcinomas and cell lines reveal frequent and
RT   multiple alterations in the p53 and Rb-1 tumor-suppressor genes.";
RL   Oncogene 7:1503-1511(1992).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=7961102; DOI=10.1111/j.1349-7006.1994.tb02898.x; PMCID=PMC5919355;
RA   Suwa H., Yoshimura T., Yamaguchi N., Kanehira K., Manabe T.,
RA   Imamura M., Hiai H., Fukumoto M.;
RT   "K-ras and p53 alterations in genomic DNA and transcripts of human
RT   pancreatic adenocarcinoma cell lines.";
RL   Jpn. J. Cancer Res. 85:1005-1014(1994).
//
RX   PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159;
RA   Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L.,
RA   Veltman J.A., van Kessel A.G., Hoglund M.;
RT   "Genome-wide array-based comparative genomic hybridization reveals
RT   multiple amplification targets and novel homozygous deletions in
RT   pancreatic carcinoma cell lines.";
RL   Cancer Res. 64:3052-3059(2004).
//
RX   PubMed=15688027; DOI=10.1038/sj.onc.1208383;
RA   Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H.,
RA   Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.;
RT   "Microarray analyses reveal strong influence of DNA copy number
RT   alterations on the transcriptional patterns in pancreatic cancer:
RT   implications for the interpretation of genomic amplifications.";
RL   Oncogene 24:1794-1801(2005).
//
RX   PubMed=25167228; DOI=10.1038/bjc.2014.475; PMCID=PMC4453732;
RA   Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C.,
RA   Linnartz R., Zubel A., Slamon D.J., Finn R.S.;
RT   "KRAS mutational subtype and copy number predict in vitro response of
RT   human pancreatic cancer cell lines to MEK inhibition.";
RL   Br. J. Cancer 111:1788-1801(2014).
//
RX   PubMed=27259358; DOI=10.1074/mcp.M116.058313; PMCID=PMC4974343;
RA   Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M.,
RA   Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K.,
RA   Biankin A.V., Wu J.-M., Daly R.J.;
RT   "Resolution of novel pancreatic ductal adenocarcinoma subtypes by
RT   global phosphotyrosine profiling.";
RL   Mol. Cell. Proteomics 15:2671-2685(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//